AI Drugmaker Investors Seek Final OK For $9.75M Fraud Deal
A class of investors in the artificial intelligence-driven drugmaker BioXcel Therapeutics Inc. has moved for final approval of a $9.75 million settlement to resolve claims that the stock price plunged after...To view the full article, register now.
Already a subscriber? Click here to view full article